SOLVING THE TOUGHEST CHALLENGES IN
PHARMACEUTICAL BOTTLE UNSCRAMBLING:
Holmach Ltd and Posimat Offer Aseptic Excellence - Delivering Uncompromised Cleanliness,
Accuracy, and Uptime for Critical OTC Products
Facing paramount GMP standards
and escalating pressures for
product integrity, patient safety,
and operational efficiency,
pharmaceutical manufacturers
require robust manufacturing
solutions. Holmach Ltd is proud to
offer Posimat’s ASEPTIC series of
specialised unscrambling solutions
for the pharmaceutical and cosmetic
industries. Drawing on 40 years of
empty container handling expertise,
Posimat’s unscramblers deliver
unparalleled hygiene, precision, and
reliability. The ASEPTIC model, in
particular, is engineered for very
small bottles like nasal sprays and
droppers, directly addressing the
critical challenges of maintaining
product integrity and achieving
operational excellence for the most
sensitive OTC products.

Built to the highest GMP
manufacturing guidelines, Posimat’s
pharmaceutical unscramblers
incorporate high-quality materials
such as stainless steel and POM
in the product zone. They are
specifically conceived to work in
clean areas with aseptic laminar flow,
preventing dust accumulation in
corners and other places.

A crucial aspect of their hygienic
operation, directly addressing
contamination risks, is that all
equipment and parts in direct
contact with containers can be easily
extracted, inspected, and sterilised
in autoclaves, ensuring absolute
product integrity. Furthermore,
the surface finish is smooth with
no edges, and all welded seams
are continuous and electro-
polished, making them ideal for the
pharmaceutical sector.

“The pharmaceutical sector requires
absolute precision and unwavering
adherence to hygiene standards,
alongside the constant need for
efficient and flexible production,”
says Chris Holland, Managing
Director of Holmach Ltd. “Posimat’s
long-standing experience, combined
with their dedication to GMP-
compliant design and innovative
features like the ASEPTIC model,
makes them an ideal partner for our
clients. Their technology ensures
gentle handling, high efficiency, and
critical cleanliness for sensitive
OTC and pharmaceutical products,
directly addressing the complexities
faced by manufacturers.”
Posimat’s ASEPTIC unscrambler
is engineered for both efficiency
and hygiene, eliminating the need
for compressed air and complex
pneumatic systems that can
introduce contamination. It operates
with a gentle rotating central hub
and two worm screws, precisely
positioning containers while
minimising energy consumption and
contamination risks.

This gentle handling is effective for
all bottle and vial types, ensuring
careful treatment without relying
on wear-prone components
common in less advanced systems.

This design also facilitates ultra-
fast, tool-free format changes by
simply swapping guides and worm
screws, guaranteeing repeatability
and significantly reducing downtime.

With its simple design and few
moving parts, the ASEPTIC
14 CHP PACKER INTERNATIONAL update
unscrambler offers low maintenance
and is easy to operate by non-skilled
teams, cutting labour costs and the
need for specialist operators.

“The pharmaceutical
sector requires
absolute precision and
unwavering adherence
to hygiene standards”
- Chris Holland
Managing Director
Holmach Ltd
These high-efficiency rotary feeding
systems offer a small footprint,
making them suitable for various
production environments. They can
be installed either in a monobloc
configuration together with a filler
or as a stand-alone unit with its
own protective enclosure, offering
flexible integration options to suit
diverse production layouts.

Posimat also offers specialised
solutions, such as centrifugal bottle
sorters, specifically designed for very
small-sized containers commonly
found in the pharmaceutical sector,
such as 5ml and 10ml ophthalmic
drops, demonstrating their
capability to meet highly specific and
challenging market needs.

For more information on Posimat’s
pharmaceutical unscrambling
machinery or to discuss your
specific container handling
requirements, contact
Holmach Ltd
01780 749097
email info@holmach.co.uk



ACOUSIA THERAPEUTICS REACHES 50%
PATIENT ENROLLMENT MILESTONE IN
PHASE 2 PROHEAR STUDY
Acousia Therapeutics GmbH
announced that it has successfully
enrolled 50% of patients in its
ongoing Phase 2 clinical trial,
the PROHEAR Study, evaluating
ACOU085 (INN: bimokalner)
for the prevention of cisplatin-
induced hearing loss in patients
with testicular cancer undergoing
chemotherapy. treatment, improving the 5-year
survival rate from 5% to 98%.

However, its life-saving efficacy is
often overshadowed by severe side
effects, with permanent, bilateral
hearing loss among the most
debilitating. Studies indicate that
up to 80% of patients treated with
cisplatin may experience clinically
relevant hearing loss.

Cisplatin is a cornerstone in
modern oncology and is used
annually in more than 500,000
cancer patients worldwide. Its
introduction in the late 1970s
revolutionised testicular cancer
The PROHEAR Study is a placebo-
controlled, randomised, double-
blind, split-body trial in which
participants receive ACOU085, a
Kv7.4 channel activator, in one ear
and a placebo in the contralateral
ear. The study is currently being
conducted at 13 leading German
ENT university clinics and is still
actively recruiting.

“This marks a significant milestone
on Acousia’s journey to offer a
treatment for the prevention of
permanent hearing loss caused
by cisplatin,” said Professor
Hubert Löwenheim, Chair of the
Department of Otolaryngology -
Head & Neck Surgery at Tuebingen
University and Scientific Supervisor
of the study. “Preventing this often
overlooked side effect is critical for
cancer patients.”
GAME-CHANGING DEODORANT
TECHNOLOGY Berry Global has developed a patented technology for the manufacture of the roll-on balls used in the production
of roll-on deodorant applicators. The company says the technology delivers faster output to produce balls at a
consistently high quality, with minimal material wastage during production.

The new technology represents a multi-million investment by Berry and demonstrates the company’s extensive
technical and design expertise, harnessing the skills and experience of personnel across its global network to
create a game-changer for the roll-on deodorant market.

“Our new deo ball technology is a product and process technical innovation, which underlines our in-depth
knowledge of both plastic materials and their manufacturing techniques,” said Alejandre Beltran, Berry Global’s
EVP Innovation, R&D and Sustainability.

Critical to the new, patented technology is its ability to manufacture the hollow ball using a single injection
moulding tool. This features a novel insert to join the two halves of the ball together, before being over-moulded.

The four-stage process creates a smoother central join for the two halves, with zero offset, meaning less plastic
has to be grinded away during the manufacturing process.

The 1.4” is the most popular size of deodorant ball and will be used in the relevant designs within Berry’s
portfolio of deo roll-ons. Importantly, while the ball is a standard design, Berry’s technical teams work with
individual customers in the development of each deo roll-on to ensure full compatibility with their products for
consistent and reliable use by the end-consumer.

CHP PACKER INTERNATIONAL update 15